Skip to main content

Market Overview

UPDATE: Piper Jaffray Downgrades Rigel Pharmaceuticals on the Return of Fostamatinib

Share:

In a report published on Tuesday, Piper Jaffray analyst Ian Somaiya downgraded Rigel Pharmaceuticals (NASDAQ: RIGL) to Neutral and lowered the price target from $9.00 to $6.00.

In the report, Piper Jaffray stated, "Loss of commercial partner and reduced commercial potential moves us to sidelines. We continue to see fostamatinib as an approvable drug. However, we believe AZ's decision to return rights reflects the competitive nature of the RA market and the challenges fostamatinib would likely face gaining sufficient share to justify the ~$300mn in remaining milestone payments and 25-30% royalty on sales. While fostamatinib showed statistical significance in ACR20 reductions compared to placebo in both doses in OSKIRA-2, only the 100mg BID dose showed significance in OSKIRA-3 (Exhibit 1). Importantly, on a placebo adjusted basis, we believe fostamatinib came up short, with adjusted ACR20 scores of ~10-15% compared to 20%+ for Pfizer's Xeljanz, a likely driver of AZ's decision in our opinion. From a safety perspective, fostamatinib was well tolerated with no new safety signals emerging, one positive sign given lingering concerns for potential hypertension and CV events."

Rigel Pharmaceuticals closed on Monday at $4.53.

Latest Ratings for RIGL

DateFirmActionFromTo
Feb 2021HC Wainwright & Co.MaintainsBuy
Nov 2020JP MorganDowngradesOverweightNeutral
Aug 2020CitigroupMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!

Posted-In: Ian Somaiya Piper JaffrayAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
PPDBairdDowngrades48.0
OSPNSidoti & Co.Upgrades39.0
PLTSidoti & Co.Upgrades48.0
LRCXArgus ResearchMaintains725.0
ROSTLoop CapitalMaintains145.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com